Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification

Clin Chem. 2010 Oct;56(10):1599-607. doi: 10.1373/clinchem.2010.147066. Epub 2010 Aug 11.

Abstract

Background: Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices.

Methods: We obtained computed tomography (CT) scan aortic calcium scores (AoCSs) in 19 (age 49 [SD 14] years) FH patients heterozygous for the 15-kb deletion at the LDLR gene and examined associations with various indices of mineral and skeletal homeostasis.

Results: We found that mean bone mineral density (BMD) at the femoral neck in these patients did not differ from age-, sex-, and province-matched mean BMD, and we observed no association of AoCS with any marker of bone resorption. However, there were negative correlations between AoCS and serum concentrations of osteocalcin, a marker of bone formation (r = -0.64, P = 0.0034), urinary calcium (r = -0.59, P = 0.0085), and estimated glomerular filtration rate (r = -0.67, P = 0.0019).

Conclusions: We found that LDLR-deficient FH was not associated with obvious bone loss or a major disturbance in calcium homeostasis. The lack of LDLR, however, may modify osteoblast function or extracellular calcium distribution, manifesting as lower bone formation, and reduced calcium excretion, resulting in increased deposition in calcifying vascular tissue.

MeSH terms

  • Aortic Diseases / blood
  • Aortic Diseases / physiopathology*
  • Aortic Diseases / prevention & control
  • Aortography
  • Bone Density
  • Bone and Bones / physiopathology*
  • Calcinosis / blood
  • Calcinosis / physiopathology*
  • Calcinosis / prevention & control
  • Calcium / blood*
  • Female
  • Homeostasis
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / physiopathology*
  • Hyperlipoproteinemia Type II / prevention & control
  • Hypolipidemic Agents / therapeutic use
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Mutation
  • Osteocalcin / blood
  • Receptors, LDL / genetics
  • Tomography, X-Ray Computed

Substances

  • Hypolipidemic Agents
  • Lipoproteins, LDL
  • Receptors, LDL
  • Osteocalcin
  • Calcium